Diligence memo · auto-generated · as of July 2, 2026
Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience Holdings, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Amarantus Bioscience Holdings, Inc. operates in Pharmaceuticals, based in SAN FRANCISCO.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Amarantus Bioscience Holdings, Inc. has raised $6.0M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.0M on 2014-11-07.
Most recent recorded round closed around 2018-02-26.
Valuation (modeled)modeled
Provath models Amarantus Bioscience Holdings, Inc. at approximately $11M (range $227K–$90M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.19× the median modeled value of Seed Pharmaceuticals companies in 2016–2018 (71 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 18 months.
Last raise 8.3 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 10.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 45% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 19% of those peers.
Closest niche peers: Chase Therapeutics Corp, Acura Pharmaceuticals, Inc, Paragon Biosciences Skyline Capital, LLC, Phoenix PharmaLabs Inc, Saghmos Therapeutics, Inc..
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.